Petros Pharmaceuticals, Inc. (PTPI) — SEC Filings
Petros Pharmaceuticals, Inc. (PTPI) — 37 SEC filings. Latest: 10-Q (Nov 13, 2025). Includes 17 8-K, 6 10-Q, 3 S-1/A.
View Petros Pharmaceuticals, Inc. on SEC EDGAR
Overview
Petros Pharmaceuticals, Inc. (PTPI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: Petros Pharmaceuticals, Inc. reported a net income of $2,250,101 for the nine months ended September 30, 2025, a significant improvement from a net loss of $5,045,350 in the same period of 2024. This turnaround was primarily driven by a $6,973,302 gain from the assignment of subsidiaries and the Viv
Sentiment Summary
Across 37 filings, the sentiment breakdown is: 5 bearish, 31 neutral, 1 mixed. The dominant filing sentiment for Petros Pharmaceuticals, Inc. is neutral.
Filing Type Overview
Petros Pharmaceuticals, Inc. (PTPI) has filed 6 10-Q, 17 8-K, 2 10-K, 2 DEF 14A, 3 S-1/A, 1 S-1, 1 DEFA14A, 3 SC 13G/A, 1 10-K/A, 1 SC 13G with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (37)
Risk Profile
Risk Assessment: Of PTPI's 31 recent filings, 6 were flagged as high-risk, 19 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | $2,250,101 |
| EPS | N/A |
| Debt-to-Equity | 0.82 |
| Cash Position | $6,070,266 |
| Operating Margin | N/A |
| Total Assets | $6,133,468 |
| Total Debt | $2,765,381 |
Key Executives
- Dr. Fady Malik
- Ms. Jennifer Choe
Industry Context
The pharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. Companies are increasingly exploring innovative business models, including digital health solutions and Rx-to-OTC switches, to capture new market segments and diversify revenue. The shift towards integrated technology solutions for OTC switches reflects a trend of leveraging technology to enhance drug accessibility and patient engagement.
Top Tags
financials (6) · Pharmaceuticals (4) · delisting (4) · regulatory-filing (4) · 10-Q (4) · corporate-governance (4) · filing (4) · pharmaceuticals (4) · listing-standards (3) · auditor-change (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Income | $2,250,101 | for the nine months ended September 30, 2025, compared to a net loss of $5,045,350 in 2024 |
| Cash and cash equivalents | $6,070,266 | as of September 30, 2025, up from $1,718,645 at December 31, 2024 |
| Accumulated deficit | $110,958,270 | as of September 30, 2025, indicating historical losses |
| Gain from assignment of subsidiaries and Vivus settlement | $6,973,302 | a primary driver of the net income for the nine months ended September 30, 2025 |
| Change in fair value of warrant liability | $10,303,657 | a significant other income item for the nine months ended September 30, 2025 |
| Proceeds from common stock and prefunded warrants, net | $8,503,018 | contributed to increased cash from financing activities |
| Shares of common stock outstanding | 42,372,260 | as of November 12, 2025 |
| Selling, general and administrative expenses | $4,249,864 | for the nine months ended September 30, 2025, from continuing operations |
| Net Loss | $2,824,689 | for the six months ended June 30, 2024 |
| Warrant issuance costs | $10,420,982 | significant expense for the six months ended June 30, 2025 |
| Shares outstanding | 42,372,260 | as of August 13, 2025 |
| Reverse stock split ratio | 1-for-25 | effected on April 30, 2025 |
| Proceeds from common stock and prefunded warrants | $8,503,018 | contributed to increased cash flow from financing activities |
| Fair Value Adjustment of Warrants | 0.04 | Represents a financial adjustment related to warrants. |
| N/A | 12.00 | This number appears without clear context in the provided snippet. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Petros Pharmaceuticals, Inc. (PTPI)?
Petros Pharmaceuticals, Inc. has 37 recent SEC filings from Jan 2024 to Nov 2025, including 17 8-K, 6 10-Q, 3 S-1/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PTPI filings?
Across 37 filings, the sentiment breakdown is: 5 bearish, 31 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Petros Pharmaceuticals, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Petros Pharmaceuticals, Inc. (PTPI) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Petros Pharmaceuticals, Inc.?
Key financial highlights from Petros Pharmaceuticals, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PTPI?
The investment thesis for PTPI includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Petros Pharmaceuticals, Inc.?
Key executives identified across Petros Pharmaceuticals, Inc.'s filings include Dr. Fady Malik, Ms. Jennifer Choe.
What are the main risk factors for Petros Pharmaceuticals, Inc. stock?
Of PTPI's 31 assessed filings, 6 were flagged high-risk, 19 medium-risk, and 6 low-risk.
What are recent predictions and forward guidance from Petros Pharmaceuticals, Inc.?
Forward guidance and predictions for Petros Pharmaceuticals, Inc. are extracted from SEC filings as they are enriched.